Kirsten rat sarcoma viral oncogene (KRAS) G12C was identified to be a drug target and a predictor of response to the novel AMG510 drug. We showed that KRAS G12C-mutated colorectal cancer has specific clinicopathologic features and worse outcome compared to other KRAS-mutated cases. The knowledge of such distinctive traits of KRAS G12C mutations might be crucial to future translational research studies and clinical trial design.

KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target Population

Schirripa M.;Rossini D.;Businello G.;Pietrantonio F.;Bergamo F.;Dei Tos A. P.;Fassan M.;Loupakis F.
2020

Abstract

Kirsten rat sarcoma viral oncogene (KRAS) G12C was identified to be a drug target and a predictor of response to the novel AMG510 drug. We showed that KRAS G12C-mutated colorectal cancer has specific clinicopathologic features and worse outcome compared to other KRAS-mutated cases. The knowledge of such distinctive traits of KRAS G12C mutations might be crucial to future translational research studies and clinical trial design.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11577/3344030
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 14
  • ???jsp.display-item.citation.isi??? ND
social impact